Azitra Inc (AZTR)
Azitra Inc. is an early-stage clinical biopharmaceutical company focused on precision dermatology. The company develops engineered proteins and topical live biotherapeutic products aimed at treating skin diseases in the United States. Its pipeline includes ATR-04, a genetically modified S. epidermidis strain being studied in a Phase 1/2 trial for the papulopustular rash associated with epidermal growth factor receptor inhibitor therapy in cancer patients; ATR-12, a genetically modified S. epidermidis strain in a Phase 1b/2a trial for Netherton syndrome; and ATR-01, a genetically modified S. epidermidis strain expressing engineered recombinant human filaggrin, which is in the IND-enabling stage for ichthyosis vulgaris. Azitra also has a joint development agreement with Bayer related to the identification and characterization of S. epidermidis strains for topical formulations. The company was incorporated in 2014 and is headquartered in Branford, Connecticut.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-AZTR
|
$0.19
|
38.5% Upside
|
Undervalued
|
$0.78
|
457.6% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-0.2x
|
0.2x
|
—
|
2.364 M
|
-7.493 M
|
12.7%
|
74.9%
|
-11.7
|
—
|
90.3%
|
